Trial · NCT04961528
ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
NCT04961528, Phase 3, Completed, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial. Trials, record NCT04961528. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04961528
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
- NCT number
- NCT04961528
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 315 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Hemoptysis
- Interventions
- Tranexamic Acid 500 MG, Terlipressin, Placebo
- First posted
- 2021-07-14
- Last updated
- 2026-04-23
- Other registries' IDs
- eudract:2020-005931-58
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients with complete or partial resolution of hemoptysis without the use of any interventional procedure. | 3 days | Efficacy of inhaled tranexamic acid and inhaled terlipressin versus placebo (normal saline) in immediate control of mild to severe hemoptysis within the first 3 days of hospitalization. A complete resolution of hemoptysis is defined by absence of recurrence within 3 days; partial resolution is defined as hemoptysis recurrence \< 50 ml within the first 3 days |
| Secondary | Rate of complete resolution of hemoptysis within 3 days, as previously defined | 3 days | Complete resolution of hemoptysis, as previously defined |
| Secondary | Rate of partial resolution of hemoptysis defined as recurrence < 50 ml | 3 days | Partial resolution of hemoptysis, as previously defined |
| Secondary | Rate of patients with total volume of hemoptysis < 200 ml | 3 days | Total volume of hemoptysis \< 200 ml |
| Secondary | Rate of patients who need an endovascular treatment (bronchial arterial endovascular embolization) | 3 days | Need of invasive procedure such as bronchial arterial endovascular embolization |
| Secondary | Time between hospital admission and bronchial arterial endovascular embolization | 3 days | Time between hospital admission and endovascular treatment |
| Secondary | Rate of patients who need a mechanical ventilation | 3 days | Need of invasive procedure such as mechanical ventilation, |
| Secondary | Rate of specific adverse events | 3 days | Specific Adverse Events (AE) : acute myocardial ischemia, symptomatic venous thromboembolism, hyponatremia (\<130 mmol/L), bronchospasm (defined by the need of short-acting bronchodilatator). |
| Secondary | Rate of in-hospital mortality | 30 days | |
| Secondary | Rate of patients with hemoptysis recurrence | 30 days |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04961528
GET https://conductscience.org/api/trials/v1/NCT04961528/registered